𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future

✍ Scribed by Geoffrey Férir; Suzanne Kaptein; Johan Neyts; Erik De Clercq

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
227 KB
Volume
18
Category
Article
ISSN
1052-9276

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A decade ago, standard therapy against chronic hepatitis B virus infections only consisted of lamivudine or IFN‐α. Treatment with lamivudine and IFN has been compounded by, respectively, the emergence of drug‐resistant virus strains and the appearance of serious side effects. In the last 10 years, hepatitis B treatment has made much progress. Several treatments are now licensed for the treatment of patients with chronic hepatitis B and others are under development. Here, we provide an overview of the potential and mode of action of anti‐HBV agents that are currently available, and/or may become available in the near future. Foremost among these newer compounds are adefovir dipivoxil, entecavir and telbivudine. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Advances in the treatment of chronic hep
Advances in the treatment of chronic hepatitis B virus infection
✍ Adriana R. Marques; Stephen E. Straus 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 2 views

Recent advances in our understanding of the replicative mechanism of HBV, and the development of potent nucleoside analogues as clinically effective inhibitors of the HIV reverse transcriptase or herpesvirus polymerases has opened a new era in the treatment of chronic HBV infection. Single agent the

The natural history of chronic hepatitis
The natural history of chronic hepatitis B virus infection
✍ Brian J. McMahon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB 👁 2 views

Chronic hepatitis B virus (HBV) infection has a complicated course. Three phases are identified: an immune tolerant phase with high HBV DNA and normal alanine aminotransferase (ALT) levels associated with minimal liver disease; an immune active phase with high HBV DNA and elevated ALT levels with ac

Antiviral treatment of chronic hepatitis
Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside
✍ George H. Scullard; Ljudevit L. Andres; Harry B. Greenberg; Joseph L. Smith; Vin 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB 👁 1 views

Twelve of 32 patients lost HBeAg and DNA polymerase from their serum after completing antiviral therapy with interferon and/or adenine arabinoside. Three lost serum HBsAg as well. Loss of corresponding viral markers from hepatic tissue was also seen. There was improvement in symptoms, hepatic tests,

Antiviral strategies in chronic hepatiti
Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model
✍ Naomi Bishop; Gilda Civitico; Yanyan Wang; Kejian Guo; Chris Birch; Ian Gust; Dr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 947 KB

## Abstract Primary duck hepatocyte (PDH) cultures were established from ducklings congenitally infected with the duck hepatitis B virus (DHBV), plated onto feeder cell layers of irradiated human embryonic lung fibroblasts, and observed for 2 to 3 weeks. This system permitted the survival of the PD

Interferon antibodies may negate the ant
Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection
✍ Dr. Anna Suk-Fong Lok; Ching-Lung Lai; Elsie Kit-Yee Leung 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

In a randomized controlled trial of recombinant a-2a interferon for chronic hepatitis B, interferon antibodies developed in 21 (39%) of 54 Chinese adults who received IFN. No correlation was observed between sex, age, pretreatment serum ALT level or liver histological findings and the development of